Clinical Trial Update: Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating NP137 in combination with atezolizumab and bevacizumab for first-line unresectable hepatocellular carcinoma has been suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)
• NP137

Snippet

Sponsor: University Hospital, Grenoble | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: SUSPENDED